US Senate joins House to pass sweeping new health bill; could be the last bi-partisan act of Congress for quite a while






The US Senate voted overwhelmingly on Wednesday (December 7, 2016) to support sweeping legislation that will reshape the way the Food and Drug Administration approves new medicines. It will also… Read more »

Novo Nordisk to cap price increases as drug costs face more scrutiny; do two drugmakers equal a trend?






With drug companies under fire over prices, the world’s largest insulin maker plans to limit increases and join competitors by introducing a model that ties the cost of medicines to… Read more »

Valeant to keep Salix after Takeda deal blows up; it’s déjà vu all over again






Valeant Pharmaceuticals International Inc.’s (Laval Québec) talks to sell a stomach-drug business to Japan’s Takeda Pharmaceutical Co. (Osaka) for roughly $10 billion have broken down amid last-minute disagreements over price and other matters,… Read more »

Arrowhead Pharma obliterated after ditching Hep B candidate; oh, that’s right, biotechs are risky






Shares of Arrowhead Pharmaceuticals Inc. (Pasadena CA) cratered 69% to $1.44 last week (November 28 to December 2, 2016) after the company said it would stop developing all drugs being… Read more »

Trump picks healthcare “dream team;” or is it something else?






President-elect Donald Trump has assembled his healthcare “dream team.” Rep. Tom Price (R-GA), a longtime critic of the Affordable Care Act but champion of health IT legislation that reduces the burden on physicians,… Read more »

Texas reports first Zika case from local mosquito; virus is now here to stay, says WHO






Texas health officials on Monday (December 28,2016) reported the state’s first case of Zika likely spread by local mosquitoes, making Texas the second state within the continental United States to… Read more »

Juno Therapeutics halts study after more patient deaths; shares crash






Juno Therapeutics Inc.’s (Seattle WA) shares plunged 23% last week after the biopharmaceutical company voluntarily placed a mid-stage clinical trial on hold after two patients suffered cerebral edema earlier in the… Read more »

US dementia rates drop even as population ages; what gives?






The proportion of older Americans living with dementia fell between 2000 and 2012, according to a new study. The exact reasons for the drop aren’t clear yet, researchers say. “If… Read more »

Johnson & Johnson eyeing Actelion; who wouldn’t with a “pro-biotech” Trump administration?






Johnson & Johnson (New Brunswick NJ) said Friday (November 11, 2016) it is in “preliminary discussions” with Swiss drug company Actelion Pharmaceuticals Ltd. (Basel CHE), a deal that would help the… Read more »

Lilly Alzheimer’s drug, like so many others, fails; will true breakthrough happen this century?






Eli Lilly & Co. (Indianapolis RIN) said its experimental Alzheimer’s treatment failed to slow loss of cognitive ability in patients with mild symptoms, a major setback for the company and millions of… Read more »